Skip to main content
INMB
NASDAQ Life Sciences

INmune Bio's Alzheimer's Trial Featured as 'Successful Example' at Major Conference, Advances to Phase 2b/3

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.33
Mkt Cap
$32.966M
52W Low
$1.16
52W High
$11.64
52W Position info
15% above low
Off High info
89% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

INMB is trading near its 52-week low of $1.16 (15% above the low).

Summary

INmune Bio's Phase 2 MINDFuL trial for XPro™ in early Alzheimer's disease was prominently featured as a successful example at the AD/PD 2026 international conference by a leading neuroimmunologist. The presentation highlighted the trial's effective biomarker enrichment strategy and consistent efficacy signals. Critically, the company also announced positive alignment with the FDA to advance XPro™ into an integrated Phase 2b/3 registrational program. This news provides significant external validation for INmune Bio's clinical approach and drug candidate, substantially de-risking its development path. Investors will now closely monitor the initiation and progress of the registrational trial.

At the time of this announcement, INMB was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33M. The 52-week trading range was $1.16 to $11.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

INMB - Latest Insights

INMB
Nov 05, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $0.910 info
Change: -$0.265 (-23%) info
Market Cap: $27.863M info
INMB
Oct 29, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.910 info
Change: -$0.610 (-40%) info
Market Cap: $27.863M info
INMB
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.910 info
Change: -$0.500 (-35%) info
Market Cap: $27.863M info
INMB
Oct 21, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $0.910 info
Change: -$0.779 (-46%) info
Market Cap: $27.863M info
INMB
Oct 21, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.910 info
Change: -$0.720 (-44%) info
Market Cap: $27.863M info